Bioenvision, Inc.

IND application filed to test Modrenal in second indication

Published in Drug Law Weekly, March 16th, 2004

Bioenvision, Inc., (BIV) announced that it has filed an Investigational New Drug (IND) application to evaluate the efficacy of Modrenal (trilostane) in patients with androgen-independent prostate cancer.

Modrenal is approved in the United Kingdom for the treatment of advanced post-menopausal breast cancer and was commercially launched in May 2003.

The phase II open label clinical trial in prostate cancer is expected to enroll 43 patients, staged in two groups. Once a single positive response is seen in the first group of 18 patients, a further 25 will be enrolled. Enrollment is expected to take place over the next 12 months. The primary endpoint of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry